You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.


Go back

What is Incruse Ellipta?

Incruse Ellipta is an inhalation powder used to treat chronic obstructive pulmonary disease (COPD) in adults. Incruse Ellipta contains an active substance called umeclidinium bromide, which belongs to a group of medicines called bronchodilators. These block the tightening of the muscles around the airways, caused by COPD, making it easier for air to get in and out of lungs. When used regularly, it can help control your breathing difficulties and reduce the effects of COPD on your everyday life.

Incruse Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing. If you get this sort of attack you must use a quick-acting reliever inhaler (such as salbutamol).

For further information on Incruse Ellipta (umeclidinium) and potential side effects, please see:

Incruse and Ellipta are registered trademarks of the GlaxoSmithKline Group of Companies